GTHPOTCElectromedical & Electrotherapeutic ApparatusUS GAAP · USD

Guided Therapeutics Inc

Guided Therapeutics Inc. develops and commercializes the LuViva Advanced Cervical Scan, an electromedical device used for cervical cancer screening. The company’s business is centered on selling LuViva instruments and disposables through direct and distribution channels, while it continues to pursue regulatory approvals needed to expand commercial adoption.

Kysy yhtiöstä
Liikevaihto0,8milj. USD
+10 857,1 %v/v
Liikevoitto (EBIT)−2,4milj. USD
−12,5 %v/v
EBIT-marginaali−309,3%
+29 805,0 %-yks.v/v
Nettotulos−3,2milj. USD
−32,2 %v/v
Vapaa kassavirta−1,1milj. USD

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−4−3−2−101milj. USD2020: 0,10 milj. USD2020: EBIT −1,1 milj. USD20202021: 0,08 milj. USD2021: EBIT −2,4 milj. USD20212022: 0,01 milj. USD2022: EBIT −3,3 milj. USD20222023: 0,10 milj. USD2023: EBIT −3,5 milj. USD20232024: 0,01 milj. USD2024: EBIT −2,1 milj. USD20242025: 0,77 milj. USD2025: EBIT −2,4 milj. USD20250,77−2,4
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Guided Therapeutics Inc

Liiketoiminta

Osuus liikevaihdosta
LuViva devices70 %

Cervical cancer screening instruments sold as instrumentation packages to hospitals, clinics, and partners.

Disposables and consumables30 %

RFID chips and related consumable components used with LuViva systems.

Asiakkaat

The company sells primarily to medical distributors, healthcare systems, hospitals, and clinics that use LuViva for cervical cancer screening. It is also pursuing government and public-health buyers, including the Turkish Ministry of Health, because large-scale screening programs can create recurring demand for devices and disposables.

Medical distributors

Buy LuViva systems for resale and market development in approved territories.

Hospitals and clinics

Purchase devices for cervical cancer screening programs and patient throughput.

Government health ministries

Evaluate LuViva for public screening programs where scale and cost matter.

Government hospital systems

Buy devices for regional deployment, such as the Sulawesi hospital system in Indonesia.

Strategia

The company’s near-term strategy is to secure regulatory approvals, convert distributor relationships into shipments, and fund operations until commercialization scales. It is also trying to reduce execution risk by using external financial support, advance payments, and partner-led market entry rather than building a large direct-sales footprint too early.

Regulatory approvals in the U.S. and ChinaLyhyt aikaväli

Commercial scale depends on FDA and NMPA clearance, especially for the largest target markets.

Distributor-led international expansionKeskipitkä aikaväli

The company lacks a large direct sales infrastructure, so partners are essential for market access.

Cash preservation and external fundingLyhyt aikaväli

The business remains loss-making and needs capital to continue operations and commercialization.

Maantiede

Guided Therapeutics is still a small-revenue company, but its commercial focus spans the United States, China, and Europe, with additional activity in Turkey and Indonesia. Geography matters because sales depend heavily on local regulatory approvals, distributor execution, and the timing of market access in each country.

Riskit

Guided Therapeutics faces substantial regulatory, funding, and commercialization risk because its revenue base is still small and dependent on approvals that can be delayed or denied. The company also has concentration risk in a few markets and counterparties, while medical-device adoption depends on clinical acceptance, distributor performance, and manufacturing execution.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Regulatory approval delays2Geopolitical and country-specific market risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going concern / financing riskVaikutus: Kriittinen

    The company has recurring losses and needs additional capital to continue operations and fund studies.

    KohdistuuOperationsClinical workManufacturing readiness
  2. Regulatory approval delaysVaikutus: KorkeaTodennäköisyys: Korkea

    Sales depend on FDA and NMPA clearance, and delays directly push out revenue and cash generation.

    Kohdistuu: LuViva commercialization in the U.S. and China

  3. Distributor and counterparty riskVaikutus: Korkea

    Sales depend on partners such as SMI, Newmars, and HDMT, and one partner is in contractual default.

    KohdistuuOrder conversionCollectionsMarket access
  4. Market acceptance riskVaikutus: Korkea

    The product must gain clinical and commercial acceptance versus existing cervical screening methods.

    KohdistuuAdoption by hospitalsClinicsPublic health systems
  5. Geopolitical and country-specific market riskVaikutus: KeskitasoTodennäköisyys: Korkea

    Russia and other markets may face approval, trade, or operating constraints.

    Kohdistuu: European distribution and international expansion

Kysy Clarifolta: Guided Therapeutics Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Some customer payments are recorded as deferred revenue until shipment or approval conditions are met.

Vaikutus: Can shift revenue between quarters and affect comparability.

Deferred revenue

The company reported a sizable deferred revenue balance tied to future shipments.

Vaikutus: Indicates revenue already billed or collected but not yet recognized.

Inventory valuation

Devices and components must be written down if demand or approval timing changes.

Vaikutus: Can affect gross margin and operating results.

Fair value of equity instruments

Employee, service-provider, and investor instruments are valued using option-pricing models.

Vaikutus: Can create non-cash expense volatility.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Lisata Therapeutics, Inc

LSTA · Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

GT Biopharma, Inc.

GTBP · Pharmaceutical Preparations

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Cero Therapeutics Holdings, Inc.

CEROW · Biological Products, (No Diagnostic Substances)

LivaNova PLC

LIVN · Electromedical & Electrotherapeutic Apparatus

Päivitetty: 24.9.2026